抄録
Study Objectives: It is well known that a family history of diabetes (FHD) is a definitive risk factor for type 2 diabetes. It has not been known whether sleepdisordered breathing (SDB) increases the prevalence of diabetes in those with an FHD. Methods: We assessed SDB severity in 7, 477 study participants by oximetry corrected by objective sleep duration determined by wrist actigraphy. Glycated hemoglobin ≥6.5% and/or current medication for diabetes indicated the presence of diabetes. In addition to the overall prevalence, the prevalence of recent-onset diabetes during the nearly 5 years before the SDB measurements were made was investigated. Results: Of the 7, 477 participants (mean age: 57.9; range: 34.2-80.7; SD: 12.1 years; 67.7% females), 1, 569 had an FHD. The prevalence of diabetes in FHD participants with moderate-to-severe SDB (MS-SDB) was higher than in those without SDB (MS-SDB vs without SDB: all, 29.3% vs 3.3% [P <.001]; females, 32.6% vs 1.9% [P <.001];males, 26.2%vs 11.7%[P =.037]). However, multivariate analysis showed thatMS-SDB was significantly associated with a higher prevalence of diabetes only in FHD-positive females (odds ratio [95% confidence interval]: females, 7.43 [3.16-17.45]; males, 0.92 [0.37-2.31]). Among the FHD-positive participants, the prevalence of recent-onset diabetes was higher in those with MS-SDB than thosewithout SDB, but only in females (MS-SDB vs without SDB: 21.4% vs 1.1%; P < 0.001). Conclusions:MS-SDB was associated with diabetes risk in females with an FHD, and future studies are needed on whether treatment of SDB in females with an FHD would prevent the onset of diabetes.
本文言語 | English |
---|---|
ページ(範囲) | 129-140 |
ページ数 | 12 |
ジャーナル | Journal of Clinical Sleep Medicine |
巻 | 17 |
号 | 2 |
DOI | |
出版ステータス | Published - 2021 2月 1 |
外部発表 | はい |
ASJC Scopus subject areas
- 呼吸器内科
- 神経学
- 臨床神経学
UN SDG
この成果は、次の持続可能な開発目標に貢献しています
文献へのアクセス
他のファイルとリンク
フィンガープリント
「Impact of sleep-disordered breathing on glucose metabolism among individuals with a family history of diabetes: The Nagahama study」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。引用スタイル
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Journal of Clinical Sleep Medicine, Vol. 17, No. 2, 01.02.2021, p. 129-140.
研究成果: Article › 査読
}
TY - JOUR
T1 - Impact of sleep-disordered breathing on glucose metabolism among individuals with a family history of diabetes
T2 - The Nagahama study
AU - Nagahama Study Group
AU - Minami, Takuma
AU - Matsumoto, Takeshi
AU - Tabara, Yasuharu
AU - Gozal, David
AU - Smith, Dale
AU - Murase, Kimihiko
AU - Tanizawa, Kiminobu
AU - Takahashi, Naomi
AU - Nakatsuka, Yoshinari
AU - Hamada, Satoshi
AU - Handa, Tomohiro
AU - Takeyama, Hirofumi
AU - Oga, Toru
AU - Nakamoto, Isuzu
AU - Wakamura, Tomoko
AU - Komenami, Naoko
AU - Setoh, Kazuya
AU - Tsutsumi, Takanobu
AU - Kawaguchi, Takahisa
AU - Kamatani, Yoichiro
AU - Takahashi, Yoshimitsu
AU - Morita, Satoshi
AU - Nakayama, Takeo
AU - Hirai, Toyohiro
AU - Matsuda, Fumihiko
AU - Chin, Kazuo
N1 - Funding Information: All authors have seen and approved this manuscript. Work for this study was performed at Kyoto University and Nagahama Municipal Office. This study was funded by a University Grant; a Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology in Japan (26293198, 17H04182, 20K17860); the Center of Innovation Program; and the Global University Project from Japan Science and Technology Agency, Japan Agency for Medical Research and Development (AMED) under grant numbers dk0207006, ek0109070, ek0109283, ek0109196, ek0109348, kk0205008, ek0210066, and ek0210096, ek0210116; grants from the Japanese Ministry of Education, Culture, Sports, Science and Technology; the Intractable Respiratory Diseases and Pulmonary Hypertension Research Group from the Ministry of Health, Labor, and Welfare of Japan; the Research Foundation for Healthy Aging, and the Ministry of Health, Labour, and Welfare Sciences Research grants; Research on Region Medical (H30-31-iryo-ippan-009). D.G. is supported by National Institutes of Health grants HL130984 and HL140548. The Department of Respiratory Care and Sleep Control Medicine is funded by endowments from Philips-Respironics, ResMed, Fukuda Denshi, and Fukuda Lifetec Keiji to Kyoto University. Takuma Minami reports personal fees from Teijin Zaitakuiryou, outside the submitted work. Yasuharu Tabara reports grants from the Ministry of Education, Culture, Sports, Science and Technology in Japan and grants from Japan AMED, during the conduct of the study. Kimihiko Murase, and Hirofumi Takeyama report grants from Philips-Respironics, grants from ResMed, grants from Fukuda Denshi, grants from Fukuda Lifetec Keiji, and grants from Teijin Pharma, outside the submitted work. Naomi Takahashi and Yoshinari Nakatsuka report grants from Philips-Respironics, grants from ResMed, grants from Fukuda Denshi, and grants from Fukuda Lifetec Keiji, outside the submitted work. Toru Oga reports grants from Philips-Respironics, ResMed, Fukuda Denshi, and Fukuda Lifetec Keiji, during the conduct of the study (he previously belonged to the Department of Respiratory Care and Sleep Control Medicine, Kyoto University, which has been funded by endowments from these companies). Fumihiko Matsuda reports grants from Kyoto University; grants from the Ministry of Education, Culture, Sports, Science and Technology in Japan; grants from Japan AMED; and grants from the Takeda Medical Research Foundation, during the conduct of the study. Kazuo Chin reports grants from the Japanese Ministry of Education, Culture, Sports, Science, and Technology; grants from the Center of Innovation Program and the Global University Project from Japan Science and Technology Agency; the Japan AMED, during the conduct of the study; grants and personal fees from Philips-Respironics; grants and personal fees from ResMed; grants and personal fees from Fukuda Denshi; grants and personal fees from Fukuda Lifetec Keiji; grants and personal fees from Teijin Pharma; grants from Kyorin Pharmaceutical Co, Ltd; grants from Nippon Boehringer Ingelheim Co, Ltd; grants and personal fees from GlaxoSmithKline; personal fees from MSD; personal fees from Astellas Pharma; personal fees from Eisai Co, Ltd; grants and personal fees from Resmed Japan; personal fees from Mylan EPO; Research Grants on Region Medical (H30-31-iryo-ippan-009) from the Ministry of Health, Labor and Welfare in Japan; and grants from the Intractable Respiratory Diseases and Pulmonary Hypertension Research Group from the Ministry of Health, Labor and Welfare of Japan, outside the submitted work. The other authors report no conflicts of interest. Funding Information: All authors have seen and approved this manuscript. Work for this study was performed at Kyoto University and Nagahama Municipal Office. This study was funded by a University Grant; a Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology in Japan (26293198, 17H04182, 20K17860); the Center of Innovation Program; and the Global University Project from Japan Science and Technology Agency, Japan Agency for Medical Research and Development (AMED) under grant numbers dk0207006, ek0109070, ek0109283, ek0109196, ek0109348, kk0205008, ek0210066, and ek0210096, ek0210116; grants from the Japanese Ministry of Education, Culture, Sports, Science and Technology; the Intractable Respiratory Diseases and Pulmonary Hypertension Research Group from the Ministry of Health, Labor, and Welfare of Japan; the Research Foundation for Healthy Aging, and the Ministry of Health, Labour, andWelfare Sciences Research grants; Research on Region Medical (H30-31-iryo-ippan-009). D.G. is supported by National Institutes of Health grants HL130984 and HL140548. The Department of Respiratory Care and Sleep Control Medicine is funded by endowments from Philips-Respironics, ResMed, Fukuda Denshi, and Fukuda Lifetec Keiji to Kyoto University. Takuma Minami reports personal fees from Teijin Zaitakuiryou, outside the submitted work. Yasuharu Tabara reports grants from the Ministry of Education, Culture, Sports, Science and Technology in Japan and grants from Japan AMED, during the conduct of the study. Kimihiko Murase, and Hirofumi Takeyama report grants from Philips-Respironics, grants from ResMed, grants from Fukuda Denshi, grants from Fukuda Lifetec Keiji, and grants from Teijin Pharma, outside the submitted work. Naomi Takahashi and Yoshinari Nakatsuka report grants from Philips-Respironics, grants from ResMed, grants from Fukuda Denshi, and grants from Fukuda Lifetec Keiji, outside the submitted work. Toru Oga reports grants from Philips-Respironics, ResMed, Fukuda Denshi, and Fukuda Lifetec Keiji, during the conduct of the study (he previously belonged to the Department of Respiratory Care and Sleep Control Medicine, Kyoto University, which has been funded by endowments from these companies). Fumihiko Matsuda reports grants from Kyoto University; grants from the Ministry of Education, Culture, Sports, Science and Technology in Japan; grants fromJapan AMED; and grants from the Takeda Medical Research Foundation, during the conduct of the study. Kazuo Chin reports grants from the Japanese Ministry of Education, Culture, Sports, Science, and Technology; grants from the Center of Innovation Program and the Global University Project from Japan Science and Technology Agency; the Japan AMED, during the conduct of the study; grants and personal fees from Philips-Respironics; grants and personal fees from ResMed; grants and personal fees from Fukuda Denshi; grants and personal fees from Fukuda Lifetec Keiji; grants and personal fees from Teijin Pharma; grants from Kyorin Pharmaceutical Co, Ltd; grants from Nippon Boehringer Ingelheim Co, Ltd; grants and personal fees from GlaxoSmithKline; personal fees from MSD; personal fees from Astellas Pharma; personal fees from Eisai Co, Ltd; grants and personal fees from Resmed Japan; personal fees from Mylan EPO; Research Grants on Region Medical (H30-31-iryo-ippan-009) from the Ministry of Health, Labor and Welfare in Japan; and grants from the Intractable Respiratory Diseases and Pulmonary Hypertension Research Group from the Ministry of Health, Labor and Welfare of Japan, outside the submitted work. The other authors report no conflicts of interest. Publisher Copyright: © 2021 American Academy of Sleep Medicine. All rights reserved.
PY - 2021/2/1
Y1 - 2021/2/1
N2 - Study Objectives: It is well known that a family history of diabetes (FHD) is a definitive risk factor for type 2 diabetes. It has not been known whether sleepdisordered breathing (SDB) increases the prevalence of diabetes in those with an FHD. Methods: We assessed SDB severity in 7, 477 study participants by oximetry corrected by objective sleep duration determined by wrist actigraphy. Glycated hemoglobin ≥6.5% and/or current medication for diabetes indicated the presence of diabetes. In addition to the overall prevalence, the prevalence of recent-onset diabetes during the nearly 5 years before the SDB measurements were made was investigated. Results: Of the 7, 477 participants (mean age: 57.9; range: 34.2-80.7; SD: 12.1 years; 67.7% females), 1, 569 had an FHD. The prevalence of diabetes in FHD participants with moderate-to-severe SDB (MS-SDB) was higher than in those without SDB (MS-SDB vs without SDB: all, 29.3% vs 3.3% [P <.001]; females, 32.6% vs 1.9% [P <.001];males, 26.2%vs 11.7%[P =.037]). However, multivariate analysis showed thatMS-SDB was significantly associated with a higher prevalence of diabetes only in FHD-positive females (odds ratio [95% confidence interval]: females, 7.43 [3.16-17.45]; males, 0.92 [0.37-2.31]). Among the FHD-positive participants, the prevalence of recent-onset diabetes was higher in those with MS-SDB than thosewithout SDB, but only in females (MS-SDB vs without SDB: 21.4% vs 1.1%; P < 0.001). Conclusions:MS-SDB was associated with diabetes risk in females with an FHD, and future studies are needed on whether treatment of SDB in females with an FHD would prevent the onset of diabetes.
AB - Study Objectives: It is well known that a family history of diabetes (FHD) is a definitive risk factor for type 2 diabetes. It has not been known whether sleepdisordered breathing (SDB) increases the prevalence of diabetes in those with an FHD. Methods: We assessed SDB severity in 7, 477 study participants by oximetry corrected by objective sleep duration determined by wrist actigraphy. Glycated hemoglobin ≥6.5% and/or current medication for diabetes indicated the presence of diabetes. In addition to the overall prevalence, the prevalence of recent-onset diabetes during the nearly 5 years before the SDB measurements were made was investigated. Results: Of the 7, 477 participants (mean age: 57.9; range: 34.2-80.7; SD: 12.1 years; 67.7% females), 1, 569 had an FHD. The prevalence of diabetes in FHD participants with moderate-to-severe SDB (MS-SDB) was higher than in those without SDB (MS-SDB vs without SDB: all, 29.3% vs 3.3% [P <.001]; females, 32.6% vs 1.9% [P <.001];males, 26.2%vs 11.7%[P =.037]). However, multivariate analysis showed thatMS-SDB was significantly associated with a higher prevalence of diabetes only in FHD-positive females (odds ratio [95% confidence interval]: females, 7.43 [3.16-17.45]; males, 0.92 [0.37-2.31]). Among the FHD-positive participants, the prevalence of recent-onset diabetes was higher in those with MS-SDB than thosewithout SDB, but only in females (MS-SDB vs without SDB: 21.4% vs 1.1%; P < 0.001). Conclusions:MS-SDB was associated with diabetes risk in females with an FHD, and future studies are needed on whether treatment of SDB in females with an FHD would prevent the onset of diabetes.
KW - Effect modification
KW - Environment
KW - Gene
KW - Heritability
KW - Obstructive sleep apnea
UR - http://www.scopus.com/inward/record.url?scp=85098543124&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85098543124&partnerID=8YFLogxK
U2 - 10.5664/JCSM.8796
DO - 10.5664/JCSM.8796
M3 - Article
C2 - 32955012
AN - SCOPUS:85098543124
SN - 1550-9389
VL - 17
SP - 129
EP - 140
JO - Journal of Clinical Sleep Medicine
JF - Journal of Clinical Sleep Medicine
IS - 2
ER -